Abstract: Objective To study the clinical effect of vasodilators combined with sedatives in the treatment of patients with coronary heart disease (CHD) with depression patients. Methods A total of 50 CHD patients with depression treated from June 2020 to September 2021 in Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine were selected for the study. The patients were divided into group A and group B according to random number table method, with 25 cases in each group. Group B was treated with vasodilators alone, and group A was treated with vasodilators combined with sedatives. The clinical effect of the two groups after intervention were compared. The degree of depression of the two groups was evaluated by self-rating depression scale (SDS), and the quality of life of the two groups was evaluated by Seattle angina pectoris quality of life scale (SAQ). At the same time, the changes in indicators of the left ventricular ejection fraction (LVEF), left ventricular end systolic volume index (LVESVI), high-sensitivity Creactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) were measured. Results There were no significant differences in the indicators of LVEF, LVESVI, hs-CRP and TNF-α between the two groups before treatment (P>0.05).After treatment, the indicators of LVEF of the two groups were higher than those before treatment, the indicators of LVESVI, hs-CRP and TNF-α of the two groups were lower than those before treatment, the indicators of LVEF in group A after treatment was higher than that in group B, the indicators of LVESVI, hs-CRP and TNF-α in group A after treatment were lower than those in group B, and the differences were statistically significant (P<0.05). There were no significant differences in the scores of SDS and SAQ between the two groups before treatment (P>0.05). The SDS scores of the two groups after treatment were lower than those before treatment, and the SAQ scores of the two groups after treatment were higher than those before treatment, the SDS score of group A after treatment was lower than that of group B, and the SAQ score of group A after treatment was higher than that of group B, the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion For CHD patients with depression, the treatment of vasodilators combined with sedatives has a good clinical effect, which can promote the recovery of prognosis, improve the indexes of cardiac function, reduce the indexes of inflammatory factors, reduce the degree of depression, improve the prognosis and improve the quality of life of patients, which is worthy of reference.
李幸洲;徐玉莲. 扩血管药物联合镇静药在伴抑郁的冠心病患者中的应用效果[J]. 中国当代医药, 2022, 29(16): 91-94转99.
LI Xingzhou; XU Yulian. Application effect of vasodilators combined with sedatives in patients with coronary heart disease with depression. 中国当代医药, 2022, 29(16): 91-94转99.